Ertapenem Dosing for Adults
For adults with normal renal function (creatinine clearance >30 mL/min/1.73 m²), administer ertapenem 1 gram IV or IM once daily; for severe renal impairment (creatinine clearance ≤30 mL/min/1.73 m²) or end-stage renal disease, reduce the dose to 500 mg once daily. 1
Standard Dosing in Normal Renal Function
- Dose: 1 gram once daily (IV or IM)
- Infusion time: 30 minutes for IV administration
- Maximum duration: Up to 14 days for IV, up to 7 days for IM
- No adjustment needed for age, gender, weight, or hepatic impairment 1
The once-daily dosing is a key advantage of ertapenem compared to other carbapenems, making it suitable for outpatient parenteral antimicrobial therapy 2.
Renal Impairment Dosing
Creatinine Clearance >30 mL/min/1.73 m²
- No dose adjustment required - continue 1 gram once daily 1
Severe Renal Impairment (CrCl ≤30 mL/min/1.73 m²)
- Reduce to 500 mg once daily 1
- This adjustment is critical because ertapenem's area under the curve increases by 158% in advanced renal insufficiency and 192% in end-stage renal disease 3
Hemodialysis Patients
Critical timing considerations:
- If ertapenem is given within 6 hours before hemodialysis: Give supplementary dose of 150 mg after dialysis 1
- If ertapenem is given ≥6 hours before hemodialysis: No supplementary dose needed 1
- Hemodialysis removes approximately 30% of the ertapenem dose 3
Important caveat: The standard 500 mg daily dose in hemodialysis patients carries a 10% risk of neurotoxicity, particularly in elderly males with dementia or concurrent use of other beta-lactams, aminoglycosides, or fluoroquinolones 4. Consider alternative post-dialysis dosing strategies (1 gram loading dose followed by 500 mg for 48-hour interdialytic intervals or 1 gram for 72-hour intervals) though these require further validation 4.
Estimating Creatinine Clearance
When only serum creatinine is available, use the Cockcroft-Gault equation 1:
- Males: CrCl = [weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)]
- Females: CrCl = 0.85 × male calculation
Special Populations
Hepatic Impairment
- No dose adjustment recommendations available - insufficient data 1
Critically Ill Patients
- Standard 1 gram every 24 hours may be inadequate for patients with creatinine clearance ≥60 mL/min 5
- Divided dosing (e.g., 500 mg every 12 hours) may optimize both efficacy and safety in this population, though this requires further validation 5
- Only achieves >80% probability of target attainment in critically ill patients with CrCl 30-59 mL/min 5
Obesity
- No dose adjustment required based on body weight 6, 2
- Standard dosing provides adequate tissue concentrations for most infections, though data for osteomyelitis caused by Staphylococcus species may be insufficient 6
Key Safety Considerations
Neurotoxicity risk factors (particularly seizures):
- Advanced age (especially >70 years)
- Male sex
- Dementia or pre-existing neurological conditions
- Renal impairment
- Concurrent use of other beta-lactams, aminoglycosides, or fluoroquinolones
- History of epilepsy (even if well-controlled) 4, 7
Monitor closely in patients with these risk factors and discontinue immediately if neurological symptoms develop, as they are typically reversible 7.